acetrizoic acid acetrizoic acid acetrizoic acid is a pharmaceutical drug that was used as an iodinated contrast medium for x-ray imaging. it was applied in form of its salt, sodium acetrizoate, but is no longer in clinical use. acetrizoic acidclinical datatrade namesurokon, triurol, salpix, othersahfs/drugs.cominternational drug namesatc codev08aa07 (who) identifiers iupac name 3-acetamido-2,4,6-triiodobenzoic acid cas number85-36-9 nna salt: 129-63-5pubchem cid6806na salt: 8517drugbankdb09347 nchemspider6547 yna salt: 8203unii24256bqv7mna salt: 5gf4b2i1ddkeggd02457 ychemblchembl1201327 nna salt: chembl1201045comptox dashboard (epa)dtxsid2022549 echa infocard100.001.455 chemical and physical dataformulac9h6i3no3molar mass556.864 g·mol−13d model (jsmol)interactive image smiles o=c(nc1c(i)c(c(i)cc1i)c(=o)o)c inchi inchi=1s/c9h6i3no3/c1-3(14)13-8-5(11)2-4(10)6(7(8)12)9(15)16/h2h,1h3,(h,13,14)(h,15,16) ykey:gnogsfbxbwbtig-uhfffaoysa-n y ny (what is this?) (verify) chemistry and mechanism of action the substance has high osmolality and is water-soluble. the three iodine atoms in the molecule readily absorb x-rays and are therefore responsible for its usability as a contrast medium. history acetrizoate was developed by v.h. wallingford of mallinckrodt, and introduced in 1950; it was employed as a contrast agent for several radiographic studies, including pyelography, angiography of the brain, carotid arteries and the aorta, and cholecystography. it was soon found to be highly toxic to the kidneys and nervous system—work urging caution in its administration was published as early as 1959, after reports of adverse reactions ranging from hypersensitivity to brain damage—and was eventually replaced by other agents with higher efficacy and lower toxicity, such as sodium diatrizoate, a closely related compound. trade names trade names include urokon, triurol and salpix, as well as gastrografina and urografina in portugal.